Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 786 participants.

Also called NCT07347626

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 786 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07347626
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07347626. Randomized; single masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2029-09-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis
Acronym
E-TWIST
Condition
Acute Ischemic Stroke
Intervention (Drug)
Eptifibatide (Integrilin)
Intervention (Drug)
Standard Medical Therapy
Lead sponsor
Xinqiao Hospital of Chongqing (class: other)
Collaborator
The First Affiliated Hospital of Hainan Medical University (class: other government)
Collaborator
The First Affiliated Hospital of Nanchang University (class: other)

Record details

Record id
cardio:ct-nct07347626
Content hash
9b04295553c7be2ed6a5a4082b78327cf4bbc9e36c59c34ac1f3d9137735c842